10.58  5.12 (93.77%)		12-30 16:00
Open: 8.75 High: 12.7 Volume: 109,228,442		Pre. Close: 5.46 Low: 7.8001 Market Cap: 28(M)

Short term
Mid term
Targets	6-month :	14.83	1-year :	17.32
Resists	First :	12.69	Second :	14.83
Pivot price	5.36
Supports	First :	7.01	Second :	3.5
MAs	MA(5) :	6.47	MA(20) :	5.11
	MA(100) :	4.56	MA(250) :	0
MACD	MACD :	0.6	Signal :	0.2
%K %D	K(14,3) :	87.7	D(3) :	92.7
RSI	RSI(14): 90.8
52-week	High :	14.97	Low :	2.73

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ EKSO ] has closed above the upper band by 41.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 349.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	12.71 - 12.76	12.76 - 12.81
Low:	7.71 - 7.75	7.75 - 7.79
Close:	10.49 - 10.58	10.58 - 10.65

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

Tue, 30 Dec 2025
Ekso Bionics stock nearly doubles as Applied Digital cloud deal points to ChronoScale pivot - ts2.tech

Tue, 30 Dec 2025
EKSO Stock Soars: An Unexpected Surge - StocksToTrade

Tue, 30 Dec 2025
Applied Digital to spin out cloud computing business, combine it with robotics company - The Business Journals

Tue, 30 Dec 2025
Ekso Bionics Stock Soars 103% After Applied Digital Proposes Cloud Spin-Out - Nasdaq

Tue, 30 Dec 2025
Applied Digital Stock Moves Higher on Spin-Off Buzz - Finviz

Tue, 30 Dec 2025
APLD Stock In Spotlight After Analysts Say Cloud Business Spinoff And EKSO Merger Could Unlock Value - Stocktwits

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	3 (M)
Shares Float	2 (M)
Held by Insiders	5.8 (%)
Held by Institutions	7.7 (%)
Shares Short	92 (K)
Shares Short P.Month	62 (K)

EPS	-5.39
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.69
Profit Margin	-70.8 %
Operating Margin	-33.2 %
Return on Assets (ttm)	-27.2 %
Return on Equity (ttm)	-85 %
Qtrly Rev. Growth	2.4 %
Gross Profit (p.s.)	3.01
Sales Per Share	5.62
EBITDA (p.s.)	-3.64
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-1.97
PEG Ratio	0
Price to Book value	2.86
Price to Sales	1.87
Price to Cash Flow	-3.12

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.